Vicebio, a clinical-stage biopharmaceutical company, has entered into a definitive agreement to be acquired by Sanofi. Under the terms of the agreement, Sanofi will pay up to US-$ 1.6 billion for Vicebio, including an upfront payment of US-$ 1.15 billion as well as development and regulatory milestones of US-$ 450 million.
Vicebio specializes in the development of next-generation vaccines against respiratory viral infections, using the “molecular clamp” technology invented at The University of Queensland. This unique approach is applicable to a wide range of viruses, including respiratory syncytial virus (RSV), human metapneumovirus (hMPV), parainfluenza viruses, influenza and coronaviruses, and is particularly well-suited for multivalent vaccines. Vicebio is currently running a phase 1 clinical study with a bivalent vaccine targeting RSV and hMPV.
VOSSIUS has advised Vicebio in intellectual property matters since the creation of the company and has strategically and operationally managed Vicebio’s patent portfolio under the leadership of Oswin Ridderbusch and Dr. Felix Getzke. “We are very proud of what Vicebio has achieved. Sanofi’s decision to acquire the company attests to the great promise of Vicebio’s vaccine candidates and the molecular clamp technology.” says Vossius partner Oswin Ridderbusch.